From Cutting Edge Definition of Disease to More Effective Treatments

Activity Overview

This symposium will discuss a genetically-inspired classification of MDS aimed at improving clinical decision making. The clinical relevance of genetic predisposition to myeloid malignancies will also be analyzed. Allogeneic transplantation is the only potentially curative treatment for MDS but is associated with substantial morbidity and mortality; evidence that transplantation can improve survival rates for older patients with higher-risk MDS will be presented. Finally, you will hear case-based presentations focused on MDS patients with cardiovascular comorbidity, those with TP53 mutation, and anemic patients with clonal cytopenia of undetermined significance (CCUS).

Agenda Topics

• While the WHO Classification of MDS has Helped our Patients, We Should Now Move to a Genetically-Inspired Classification
• When and How Genetic Predisposition to MDS Should be Taken into Account in Clinical Decision Making
• Can Transplantation Improve Survival Rates For Older Patients with Higher-Risk MDS
• An Elderly Patient With MDS, Thrombocytopenia, and a Cardiovascular Comorbidity that Requires Anticoagulation or Antiplatelet Therapy
• A Patient with a Myeloid Neoplasm and a TP53 Mutation
• An Anemic Patient with CCUS

Learning Objectives

• Upon completion of the educational activity, participants should be able to:
• Discuss how to use molecular profiling in for the classification and management of MDS
• Evaluate genetic predisposition in the management of MDS
• Assess the eligibility for allogeneic stem cell transplantation in older patients with MDS
• Discuss how to treat elderly patient with MDS, thrombocytopenia, and a cardiovascular comorbidity that requires anticoagulation or antiplatelet therapy
• Review to treat MDS patients with a TP53 mutation
• Discuss how to treat an anemic patient with CCUS